Supply of Bluetongue Serotype 3 (BTV-3) Vaccine

The Authority is seeking to identify existing and potential suppliers of bluetongue serotype 3 (BTV-3) vaccine who have product currently under development . We are keen to understand the timelines for applications to the Veterinary Medicines Directorate (VMD) for a marketing authorisation or for emergency use consideration under Schedule 4 of the Veterinary Medicine Regulations 2013, as well as for production timescales for any product to be made available to the UK market. <br/><br/>The Authority is specifically interested in:<br/>- the types of inactivated or novel (e.g. RNA) BTV-3 vaccine being developed.<br/>- the efficacy and period (onset and duration) of immunity they might offer.<br/>- which species they are being developed for<br/>- available safety data in the target species<br/>- the proposed number of doses in the vaccination schedule, <br/>- storage conditions<br/>- readiness to submit the necessary information to the Veterinary Medicines Directorate<br/>- the extent to which the UK livestock sector could be supplied with such product in 2024 or 2025 <br/>- any information that might be provided about potential costs; any expectations around the vaccines being manufactured under the conditions of Good Manufacturing Practice (GMP). <br/><br/>The Authority will not be considering live bluetongue vaccines. <br/><br/>The Authority is seeking this information to inform decisions around guarantees of supply to the UK market. An estimated total value is therefore not provided at this stage.